Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/7596Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Tzoanopoulos, D. | en |
| dc.contributor.author | Speletas, M. | en |
| dc.contributor.author | Arvanitidis, K. | en |
| dc.contributor.author | Veiopoulou, C. | en |
| dc.contributor.author | Kyriaki, S. | en |
| dc.contributor.author | Thyphronitis, G. | en |
| dc.contributor.author | Sideras, P. | en |
| dc.contributor.author | Kartalis, G. | en |
| dc.contributor.author | Ritis, K. | en |
| dc.date.accessioned | 2015-11-24T16:32:52Z | - |
| dc.date.available | 2015-11-24T16:32:52Z | - |
| dc.identifier.issn | 0007-1048 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/7596 | - |
| dc.rights | Default Licence | - |
| dc.subject | irf-1 | en |
| dc.subject | chronic myeloid leukaemia | en |
| dc.subject | interferon | en |
| dc.subject | exon skipping | en |
| dc.subject | non-isotopic rnase cleavage assay | en |
| dc.subject | chronic myelogenous leukemia | en |
| dc.subject | sequence binding-protein | en |
| dc.subject | cytogenetic response | en |
| dc.subject | factor-i | en |
| dc.subject | transcription factor | en |
| dc.subject | irf-1 | en |
| dc.subject | alpha | en |
| dc.subject | gene | en |
| dc.subject | mutation | en |
| dc.subject | cells | en |
| dc.title | Low expression of interferon regulatory factor-1 and identification of novel exons skipping in patients with chronic myeloid leukaemia | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | <Go to ISI>://000178348000007 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών και Τεχνολογιών. Τμήμα Βιολογικών Εφαρμογών και Τεχνολογιών | el |
| heal.publicationDate | 2002 | - |
| heal.abstract | Chronic myeloid leukaemia (CML) is a malignant clonal disorder of the haematopoietic stem cell. Treatment of CML patients with interferon alpha (IFN-alpha) has induced haematological and cytogenetic remission. Interferons transcriptionally activate target genes through the JAK-STAT and interferon regulated factors (IRFs) family pathways. Interferon regulated factor-1 (IRF-1) is a transcriptional activator of genes critical for cell growth, differentiation and apoptosis. The skipping of exons 2 or 2 and 3 of IRF-1 in patients with myelodysplastic syndromes and acute myelogenous leukaemia suggests that this factor may have a critical role in leukaemogenesis. The role of IRF-1 in CML is currently unknown. Therefore, mutational analysis of IRF-1 was performed and its expression pattern was also studied in CML patients. We studied IRF-1 in peripheral blood mononuclear cells of 21 patients in chronic phase CML. No point mutations were identified at the cDNA level. Surprisingly, fourfold reduction of full-length IRF-1 mRNA expression was established in 17/21 patients compared with normal individuals. Low expression of full-length IRF-1 was observed in conjunction with high levels of aberrantly spliced mRNAs, reported for the first time. In three patients who were also analysed during blastic transformation, further reduction of full-length IRF-1 mRNA was observed. These findings demonstrate that, in CML patients, IRF-1 can produce high levels of aberrant spliced mRNAs with subsequent reduction in the levels of full-length IRF-1 mRNA. This observation is consistent with the notion that exon skipping may constitute another mechanism of tumour suppressor gene inactivation in this disease. | en |
| heal.journalName | Br J Haematol | en |
| heal.journalType | peer reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
